Perrigo Primed For M&A; Sheds Elan Asset
This article was originally published in The Pink Sheet Daily
Executive Summary
The now Dublin-based private-label nutrition company is hoping to add to its specialty generics offerings and its “promotable” brands with tuck-in acquisitions.
You may also be interested in...
Perrigo Consumer Product Growth Slows While Overall Sales Climb
The private labeler reported $53 million in new product sales for its Q2, but says the return to stores of branded OTCs, which had been recalled due to manufacturing problems, continues to diminish its consumer health product sales growth.
Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
Perrigo is using Elan’s beneficial tax rates to launch its international expansion and the royalty stream from Tysabri to help fund those M&A endeavors, but is not dramatically changing its OTC focus.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.